New report on HIV drug resistance: Challenges and recommendations

NewsGuard 100/100 Score

The World Health Organization's (WHO) latest HIV Drug Resistance (HIVDR) Report tells us where drug resistance is growing and offers recommendations for countries to monitor and respond to the potential challenges.

The report shares some good news and some concerning news. It highlights high levels of HIV viral load suppression (>90%) in populations receiving dolutegravir (DTG)-containing antiretroviral therapy (ART). However, observational and country-generated survey data indicate that levels of HIVDR to DTG are exceeding levels observed in clinical trials.

Since 2018, WHO has recommended use of dolutegravir as the preferred first- and second-line HIV treatment for all population groups. It is more effective, easier to take, and has fewer side effects than other drugs currently in use. It also has a high genetic barrier to developing drug resistance.

However, among the four surveys reported, levels of resistance to dolutegravir ranged from 3.9% to 8.6%, and reached 19.6% among people experienced with treatment and transitioned to a DTG-containing ART while having high HIV viral loads. To date, only a few countries have reported survey data to WHO.

The worrying evidence of resistance in individuals with unsuppressed viral load despite dolutegravir treatment underscores the necessity for increased vigilance and intensified efforts to optimize the quality of HIV care delivery. Standardized surveillance of HIV drug resistance is essential for effectively preventing, monitoring, and responding to these challenges".

Dr. Meg Doherty, Director, WHO Department of the Global HIV, Hepatitis and STI Programmes

Haiti was the only country to report data from a survey of HIVDR among ART naïve infants or infants starting ART for the first time. One infant, whose mother had received DTG-based ART, was found to have DTG resistance. Effective management of high viral loads among pregnant and breastfeeding women is critical to prevent transmitting HIV to infants. Increasing routine surveillance for HIVDR among infants newly diagnosed with HIV not yet taking HIV treatment will be important to guide appropriate ART options for the future.

Global targets off track

In 2022, more than 75% of the 39 million people living with HIV globally were receiving HIV treatment. Countries have implemented the WHO recommendations with 116 of 127 having adopted WHO preferred first-line DTG-based treatment for adults and adolescents, and 74% of reporting low- and middle-income countries adopted viral load monitoring for adults and adolescents.

But progress towards the SDG targets has stalled as there were still an estimated 1.3 million new HIV infections and 630 000 deaths from HIV-related causes. Between 2017 and 2022, for most countries reporting through the Global AIDS Monitoring (GAM) system, programmatic quality indicators for HIV treatment did not achieve established global targets, which further highlights the need to proactively improve the quality of HIV treatment and care services.

In 2022, only 12 of 45 WHO focus countries reported conducting surveys or had integrated the monitoring of HIVDR early warning indicators into routine monitoring and evaluation systems. Many countries continue to miss the mark when it comes to optimizing retention in care, population-level viral load suppression, and switching people with virological failure to different regimens. Additionally, antiretroviral drug stock-outs continue to happen which may negatively impact patient treatment adherence.

WHO recommends that countries routinely implement standardized surveillance of HIVDR to follow the prevalence and patterns of resistance among people not achieving suppressed viral load. This is critical, as information and data from surveys influence the development of treatment guidelines and inform the quality of treatment programmes.

Recommended guidance for country action

The report also documents cases of resistance to integrase-strand transfer inhibitors (INSTIs) after recent exposure to cabotegravir (CAB-LA). Delayed detection and confirmation of HIV infection can increase the risk of developing resistance to INSTIs. Since 2022, WHO has recommended the use of long-acting injectable CAB-LA as an additional HIV prevention option for people at substantial risk of HIV infection.

Despite the possible risk, WHO recommends the roll-out of CAB-LA for pre-exposure prophylaxis (PrEP) and calls for the scale-up of PrEP to be accompanied by standardized surveillance of drug resistance among people testing positive for HIV while receiving PrEP.

Routine monitoring of quality-of-care indicators at both clinic and national levels, followed by addressing any suboptimal performance, remains a cornerstone for the success of ART programmes. Key quality-of-care indicators include on-time ART pick-up, retention on ART, viral load testing coverage, timely second-viral load test, ARV drug stock-outs and timely switch to second-line ART.

The new HIVDR report emphasizes the importance of strengthening data reporting systems so that countries can effectively monitor and report quality-of-care indicators. It underscores the active engagement by ART clinics and programmes in use of indicator data to develop locally appropriate and sustainable solutions. These efforts are crucial for optimizing service delivery quality, thereby reducing the emergence of drug-resistant HIV.

Minimizing the spread of HIV drug resistance is a crucial part of the broader global response to antimicrobial resistance that needs coordinated action across all government sectors and levels of society.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global HIV epidemic cannot be ended without keeping former prisoners, other patients engaged in care